These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 33452147)
1. Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy. Farley H; Poole S; Chapman S; Flight W Postgrad Med J; 2022 May; 98(1159):341-345. PubMed ID: 33452147 [TBL] [Abstract][Full Text] [Related]
2. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies. Desai M; Hine C; Whitehouse JL; Brownlee K; Charman SC; Nagakumar P Respir Med; 2022 Aug; 199():106878. PubMed ID: 35633605 [TBL] [Abstract][Full Text] [Related]
3. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease. Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165 [TBL] [Abstract][Full Text] [Related]
4. [Cystic fibrosis in childhood and adulthood]. Syunyaeva Z; Mall MA; Stahl M Inn Med (Heidelb); 2024 Jun; 65(6):538-544. PubMed ID: 38714556 [TBL] [Abstract][Full Text] [Related]
5. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567 [TBL] [Abstract][Full Text] [Related]
6. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist. Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995 [TBL] [Abstract][Full Text] [Related]
7. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. Keogh RH; Szczesniak R; Taylor-Robinson D; Bilton D J Cyst Fibros; 2018 Mar; 17(2):218-227. PubMed ID: 29311001 [TBL] [Abstract][Full Text] [Related]
8. Distribution of pathogenic variants in the CFTR gene in a representative cohort of people with cystic fibrosis in the Kingdom of Bahrain. Majed OAK; Majed FO; Almoamen NJ; Alsatrawi HB; Shehabi SD; Hrbková J; Libik M; Macek M Mol Genet Genomics; 2024 May; 299(1):52. PubMed ID: 38744777 [TBL] [Abstract][Full Text] [Related]
9. Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders. Baldwin C; Zerofsky M; Sathe M; Troendle DM; Perito ER Pancreas; 2019 Aug; 48(7):888-893. PubMed ID: 31268981 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis of Cystic Fibrosis in Nonscreened Populations. Sosnay PR; White TB; Farrell PM; Ren CL; Derichs N; Howenstine MS; Nick JA; De Boeck K J Pediatr; 2017 Feb; 181S():S52-S57.e2. PubMed ID: 28129813 [TBL] [Abstract][Full Text] [Related]
11. Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies. Bresnick K; Arteaga-Solis E; Millar SJ; Laird G; LeCamus C BMJ Open Respir Res; 2021 Dec; 8(1):. PubMed ID: 34857524 [TBL] [Abstract][Full Text] [Related]
13. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Ziedalski TM; Kao PN; Henig NR; Jacobs SS; Ruoss SJ Chest; 2006 Oct; 130(4):995-1002. PubMed ID: 17035430 [TBL] [Abstract][Full Text] [Related]
14. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
15. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine. Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274 [TBL] [Abstract][Full Text] [Related]
16. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis. Ramsey ML; Gokun Y; Sobotka LA; Wellner MR; Porter K; Kirkby SE; Li SS; Papachristou GI; Krishna SG; Stanich PP; Hart PA; Conwell DL; Lara LF Am J Gastroenterol; 2021 Dec; 116(12):2446-2454. PubMed ID: 34665155 [TBL] [Abstract][Full Text] [Related]
18. Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His. Keenan K; Dupuis A; Griffin K; Castellani C; Tullis E; Gonska T J Cyst Fibros; 2019 Mar; 18(2):265-270. PubMed ID: 30279124 [TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. McGarry ME; McColley SA Pediatr Pulmonol; 2021 Jun; 56(6):1496-1503. PubMed ID: 33470563 [TBL] [Abstract][Full Text] [Related]
20. Microbial clues lead to a diagnosis of cystic fibrosis in late adulthood. Kerr C; Morrissy D; Horgan M; Plant BJ BMJ Case Rep; 2020 Apr; 13(4):. PubMed ID: 32317365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]